 Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: Long-term outcome of patients with advanced melanoma treated with pembrolizumab

Eur J Cancer: Long-term outcome of patients with advanced melanoma treated with pembrolizumab

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

soil analysis kit

ir analysis

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Although education and awareness of the risk factors of melanoma have been improved in today's society, the number of newly diagnosed cases each year continues to increase

immunity

However, the prognosis of early stable melanoma patients treated with pembrolizumab is still unclear

Patients who participated in the KEYNOTE-001 and KEYNOTE-006 studies and were stable or had partial/complete remission at the 12th or 24th week were included

Survival analysis based on 12-week treatment response group

Of the 294 patients included in the 12th week analysis, 107 were in stable condition, of which 7 (6.

The overall survival (OS) rates at 48 months for patients with complete remission, partial remission and stable disease at week 12 were 95.

Survival analysis based on 24-week treatment response groups

At the 24th week of the analysis, similar results were observed in 241 patients

The 48-month OS rate of patients with stable disease and subsequent remission at the 12th week was 72.

Analysis based on changes in comprehensive treatment response

In summary, most patients with stable melanoma in the early stage (12 weeks) treated with pembrolizumab can obtain partial or complete remission afterwards

Most early (12 weeks) stable melanoma patients treated with pembrolizumab can later obtain partial or complete remission.

Original source:

Hamid Omid,Robert Caroline,Daud Adil et al.

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.